台灣臨床試驗主持人資料庫|TPIDB

2018-03-01 - 2021-01-04

Phase II

RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

Condition/Disease

Previously Treated Unresectable Hepatocellular Carcinoma
Test Drug

BGB-A317

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

侯明模

Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-04-01 - 2019-10-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus

Condition/Disease

Systemic Lupus Erythematosus (SLE)
Test Drug

GDC-0853

Participate Sites
8Sites

Terminated6Sites

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2017-03-01 - 2019-09-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically confirmed Duodenal Ulcer Subjects with or without Helicobacter pylori infection

Condition/Disease

Duodenal Ulcer
Test Drug

TAK-438

Participate Sites
6Sites

Terminated5Sites

邱正堂

Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2017-03-01 - 2020-06-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection

Condition/Disease

Gastric Ulcer
Test Drug

TAK-438

Participate Sites
6Sites

Recruiting5Sites

邱正堂

Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2015-07-01 - 2019-10-29

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug- Experienced Patients with Active Psoriatic Arthritis

Condition/Disease

Active Psoriatic Arthritis
Test Drug

Ixekizumab(LY2439821)

Participate Sites
8Sites

Terminated7Sites

黃毓惠

Linkou Chang Gung Medical Foundation

Division of Dermatology

藍忠亮

China Medical University Hospital-Taipei

未分科

2015-08-17 - 2017-11-30

Phase III

A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily administration of TAK-438 20 mg compared to Lansoprazole 30 mg in the Treatment of Subjects with Erosive Esophagitis

Condition/Disease

Erosive Esophagitis
Test Drug

TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂

Linkou Chang Gung Medical Foundation

Digestive System Department

侯明志

Taipei Veterans General Hospital

Digestive System Department

2015-08-17 - 2018-02-28

Phase III

A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

Condition/Disease

Erosive Esophagitis
Test Drug

TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂

Linkou Chang Gung Medical Foundation

Digestive System Department

吳登強

Kaohsiung Municipal Gangshan Hospital

未分科

2016-07-01 - 2019-12-31

Phase I/II

A Phase I/ II Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme

Condition/Disease

Glioblastoma Multiforme (GBM)
Test Drug

CAN008(APG101)

Participate Sites
3Sites

Terminated3Sites

魏國珍

Linkou Chang Gung Medical Foundation

Division of General Surgery

2016-07-01 - 2019-12-31

Phase I

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C (M7824) in subjects with metastatic or locally advanced solid tumors with expansion to selected indications in Asia

Condition/Disease

metastatic or locally advanced solid tumors
Test Drug

MSB0011359C (M7824)

Participate Sites
5Sites

Terminated5Sites

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-01-01 - 2019-11-30

Phase II

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

Condition/Disease

1. Systemic Lupus Erythematosus and Active Skin Manifestations2. Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations
Test Drug

BIIB059

Participate Sites
4Sites

Recruiting4Sites

方耀凡

Linkou Chang Gung Medical Foundation

Division of Rheumatology

Search Result

List